Assessing disability progression with the Multiple Sclerosis Functional Composite

Multiple Sclerosis

Volumn 15, Issue 8, 2009, Pages 984-997

  Rudick, Richard A ^a   Polman, C H ^b   Cohen, J A ^a   Walton, M K ^c   Miller, A E ^d   Confavreux, C ^e   Lublin, F D ^d   Hutchinson, M ^f   O'Connor, P W ^g   Schwid, S R ^h   Balcer, L J ⁱ   Lynn, F ^j   Panzara, M A ^j   Sandrock, A W ^j  

^a LERNER RESEARCH INSTITUTE   (United States)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e HÔPITAL NEUROLOGIQUE   (France)

^f ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^g ST MICHAEL'S HOSPITAL   (Canada)

^h UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j BIOGEN   (United States)

more..

Author keywords

Clinical end points; Disability progression; Multiple sclerosis; Multiple Sclerosis Functional Composite; Natalizumab; Relapsing remitting

Indexed keywords

BETA1A INTERFERON; NATALIZUMAB;

ADULT; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISABILITY SEVERITY; DISEASE COURSE; DISEASE DURATION; DRUG EFFICACY; DRUG SAFETY; EXPANDED DISABILITY STATUS SCALE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS FUNCTIONAL COMPOSITE; RELAPSE; SCORING SYSTEM; SHORT FORM 36; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; COGNITION; DISABILITY EVALUATION; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HEALTH STATUS INDICATORS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; KAPLAN-MEIERS ESTIMATE; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SENSITIVITY AND SPECIFICITY; TIME FACTORS; TREATMENT OUTCOME; UPPER EXTREMITY; WALKING;

EID: 69549098029     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509106212     Document Type: Article

References (31)

1. Kurtzke, JF. Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology 1983; 33: 1444-1452.
2. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993; 43: 655-661.
3. Johnson, KP, Brooks, BR, Cohen, JA, et al. The Copolymer 1 Multiple Sclerosis Study Group. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: Results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology 1995; 45: 1268-1276.
4. Jacobs, LD, Cookfair, DL, Rudick, RA, et al. The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996; 39: 285-294.
5. PRISMS (Prevention of Relapses and Disability by Interferon β-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/emitting multiple sclerosis. Lancet 1998; 352: 1498-1504.
6. Polman, CH, O'Connor, PW, Havrdova, E, et al. The AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
7. Rudick, RA, Stuart, WH, Calabresi, PA, et al. The SENTINEL Investigators. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
8. Kragt, JJ, Nielsen, JM, van der Linden, FAH, Uitdehaag, BM, Polman, CH. How similar are commonly combined criteria for EDSS progression in multiple sclerosis. Mult Scler 2006; 12: 782-786.
9. Whitaker, JN, McFarland, HF, Rudge, P, Reingold, SC. Outcomes assessment in multiple sclerosis clinical trials: A critical analysis. Mult Scler 1995; 1: 37-47.
10. Rudick, R, Antel, J, Confavreux, C, et al. Clinical outcomes assessment in multiple sclerosis. Ann Neurol 1996; 40: 469-479.
11. Rudick, R, Antel, J, Confavreux, C, et al. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol 1997; 42: 379-382.
12. Cutter, GR, Baier, ML, Rudick, RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122: 871-882.
13. Fischer, JS, Rudick, RA, Cutter, GR, Reingold, SC. Multiple Sclerosis Functional Composite measure (MSFC): An integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999; 5: 244-250.
14. Cohen, JA, Fischer, JS, Bolibrush, DM, et al. Intrarater and interrater reliability of the MS functional composite outcome measure. Neurology 2000; 54: 802-806.
15. Cohen, JA, Cutter, GR, Fischer, JS, et al. The IMPACT Investigators. Use of the Multiple Sclerosis Functional Composite as an outcome measure in a phase 3 clinical trial. Arch Neurol 2001; 58: 961-967.
16. Kalkers, NF, de Groot, V, Lazeron, RHC, et al. MS functional composite: relation to disease phenotype and disability strata. Neurology 2000; 54: 1233-1239.
17. Miller, DM, Rudick, RA, Cutter, G, Baier, M, Fischer, JS. Clinical significance of the Multiple Sclerosis Functional Composite: relationship to patient-reported quality of life. Arch Neurol 2000; 57: 1319-1324.
18. Rudick, RA, Cutter, G, Baier, M, et al. Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS. Neurology 2001; 56: 1324-1330.
19. Ozakbas, S, Cagiran, I, Ormeci, B, Idiman, E. Correlations between multiple sclerosis functional composite, expanded disability status scale and health-related quality of life during and after treatment of relapses in patients with multiple sclerosis. J Neurol Sci 2004; 218: 3-7.
20. Fisher, E, Rudick, RA, Cutter, G, et al. Relationship between brain atrophy and disability: An 8-year followup study of multiple sclerosis patients. Mult Scler 2000; 6: 373-377.
21. Kalkers, NF, Bergers, L, de Groot, V, et al. Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. Neurology 2001; 56: 215-219.
22. Miller, DM, Cohen, JA, Kooijmans, M, et al. The IMPACT Investigators. Change in clinician-assessed measures of multiple sclerosis and subject-reported quality of life: Results from the IMPACT study. Mult Scler 2006; 12: 180-186.
23. Uitdehaag, BMJ, Adèr, HJ, Roosma, TJA, de Groot, V, Kalkers, NF, Polman, CH. Multiple Sclerosis Functional Composite: Impact of reference population and interpretation of changes. Mult Scler 2002; 8: 366-371.
24. Fox, RJ, Lee, J-C, Rudick, RA. Optimal reference population for the multiple sclerosis functional composite. Mult Scler 2007; 13: 909-914.
25. Schwid, SR, Goodman, AD, McDermott, MP, Bever, CF, Cook, SD. Quantitative functional measures in MS: What is a reliable change. Neurology 2002; 58: 1294-1296.
26. Kaufman, M, Moyer, D, Norton, J. The significant change for the Timed 25-Foot Walk in the Multiple Sclerosis Functional Composite. Mult Scler 2000; 6: 286-290.
27. Hoogervorst, EL, Kalkers, NF, Cutter, GR, Uitdehaag, BM, Polman, CH, et al. The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite. Mult Scler 2004; 10: 55-60.
28. Kragt, JJ, van der Linden, FA, Nielsen, JM, Uitdehaag, BM, Polman, CH. Clinical impact of 20% worsening on Timed 25-foot Walk and 9-Hole Peg Test in multiple sclerosis. Mult Scler 2006; 12: 594-598.
29. Solari, A, Radice, D, Manneschi, L, Motti, L, Montanari, E. The Multiple Sclerosis Functional Composite: Different practice effects in the three test components. J Neurol Sci 2005; 228: 71-74.
30. Sipe, JC, Knobler, RL, Braheny, SL, Rice, GP, Panitch, HS, Oldstone, MB. A neurologic rating scale (NRS) for use in multiple sclerosis. Neurology 1984; 34: 1368-1372.
31. Balcer, LJ, Baier, ML, Cohen, JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology 2003; 61: 1367-1373.